A Two-Part Phase I Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XF-73 for Decolonization of Staphylococcus Aureus: A Previously Investigated 0.5 mg/g Viscosified Gel Formulation Versus a Modified Formulation

Trial Profile

A Two-Part Phase I Study to Establish and Compare the Safety and Local Tolerability of Two Nasal Formulations of XF-73 for Decolonization of Staphylococcus Aureus: A Previously Investigated 0.5 mg/g Viscosified Gel Formulation Versus a Modified Formulation

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2016

At a glance

  • Drugs Exeporfinium chloride (Primary)
  • Indications Postoperative infections; Staphylococcal infections
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Sep 2016 According to a Destiny Pharma media release, the company announced results from this study of of XF-73 for Decolonization of Staphylococcus Aureus.
    • 07 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top